Takeda Offloads Xiidra As Expected, For $3.4bn Upfront To Novartis

As widely anticipated, Takeda has reached an agreement to divest an ex-Shire ophthalmology drug, as it streamlines the combined post-acquisition business to focus on core therapeutic pillars.